{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T20:48:38Z","timestamp":1782593318643,"version":"3.54.5"},"reference-count":27,"publisher":"International Society of Global Health","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Glob Health"],"DOI":"10.7189\/jogh.14.03029","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T16:29:35Z","timestamp":1717691375000},"source":"Crossref","is-referenced-by-count":7,"title":["Excessive active pharmaceutical ingredients in substandard and falsified drugs should also raise concerns in low-income countries"],"prefix":"10.7189","volume":"14","author":[{"given":"Elisa M","family":"Maffioli","sequence":"first","affiliation":[{"name":"University of Michigan, School of Public Health, Department of Health Management and Policy, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C","family":"Mont\u00e1s","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health, Department of Global Health and Population, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chimezie","family":"Anyakora","sequence":"additional","affiliation":[{"name":"Bloom Public Health, Abuja, Nigeria"},{"name":"School of Science and Technology, Pan Atlantic University, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4223","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"key-10.7189\/jogh.14.03029-202406061748-R1","unstructured":"World Health Organization. WHO global surveillance and monitoring system for substandard and falsified medical products. Geneva: World Health Organization; 2017. Available: https:\/\/www.who.int\/publications\/i\/item\/9789241513425. Accessed: 29 March 2024."},{"key":"key-10.7189\/jogh.14.03029-202406061748-R2","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1371\/journal.pmed.1000052","article-title":"Guidelines for Field Surveys of the Quality of Medicines: A Proposal.","volume":"6","author":"Newton","year":"2009","journal-title":"PLoS Med"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R3","unstructured":"Infectious Diseases Data Observatory. Medicine Quality Scientific Literature Surveyor methodology. 2024. Available: https:\/\/www.iddo.org\/mq-scientific-literature-surveyor-methodology. Accessed: 29 March 2024."},{"key":"key-10.7189\/jogh.14.03029-202406061748-R4","doi-asserted-by":"publisher","first-page":"e181662","DOI":"10.1001\/jamanetworkopen.2018.1662","article-title":"Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.","volume":"1","author":"Ozawa","year":"2018","journal-title":"JAMA Netw Open"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R5","first-page":"19","article-title":"A bitter pill to swallow: The problem of, and solutions to, Sub-Saharan Africa\u2019s counterfeit pharmaceutical trade.","volume":"4","author":"Webb","year":"2014","journal-title":"The Columbia University Journal of Global Health"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R6","doi-asserted-by":"publisher","first-page":"e0184165","DOI":"10.1371\/journal.pone.0184165","article-title":"Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.","volume":"12","author":"Petersen","year":"2017","journal-title":"PLoS One"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R7","doi-asserted-by":"publisher","first-page":"e008587","DOI":"10.1136\/bmjgh-2022-008587","article-title":"Substandard and falsified antibiotics: Neglected drivers of antimicrobial resistance?","volume":"7","author":"Zabala","year":"2022","journal-title":"BMJ Glob Health"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R8","unstructured":"NAVADHI Market Research. Global Pharmaceuticals Industry Analysis and Trends. 2019. Available: https:\/\/www.navadhi.com\/publications\/global-pharmaceuticals-industry-analysis-and-trends-2023. Accessed: 29 March 2024."},{"key":"key-10.7189\/jogh.14.03029-202406061748-R9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/MS9.0000000000000113","article-title":"Revisiting the blind spot of substandard and fake drugs as drivers of antimicrobial resistance in LMICs.","volume":"85","author":"Gulumbe","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/bcp.12298","article-title":"Substandard drugs: a potential crisis for public health.","volume":"78","author":"Johnston","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R11","unstructured":"Pharmaceuticals Export Promotion Council of India. Regulatory & Market profile of Nigeria. India: Ministry of Commerce & Industry, Government of India; 2017. Available: https:\/\/pharmexcil.com\/uploadfile\/ufiles\/Nigeria_Regulatory_Market_Profile.pdf. Accessed: 29 March 2024."},{"key":"key-10.7189\/jogh.14.03029-202406061748-R12","doi-asserted-by":"crossref","unstructured":"Peterson K. Speculative Markets: Drug Circuits and Derivative Life in Nigeria. Durham (NC): Duke University Press; 2014.","DOI":"10.1215\/9780822376477"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2471\/BLT.19.249508","article-title":"Fostering local production of essential medicines in Nigeria.","volume":"98","author":"Fatokun","year":"2020","journal-title":"Bull World Health Organ"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R14","first-page":"690","article-title":"Nigeria leads fight against counterfeit drugs.","volume":"84","author":"Raufu","year":"2006","journal-title":"Bull World Health Organ"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R15","unstructured":"Akunyili D. The fight against counterfeit drugs in Nigeria. In: Kotalik J, Rodriguez D, editors. Transparency International-global corruption report. London, UK and Berlin, Germany: Pluto Press and Transparency International: 2006. p. 96\u2013100. Available: https:\/\/www.transparency.org\/en\/publications\/global-corruption-report-2006-corruption-and-health. Accessed: 29 May 2024."},{"key":"key-10.7189\/jogh.14.03029-202406061748-R16","unstructured":"Chinwendu O. The fight against fake drugs by NAFDAC in Nigeria. Amsterdam: Royal Tropical Institute (KIT); 2008. Available: https:\/\/nairametrics.com\/wp-content\/uploads\/2013\/04\/the-fight-against-fake-drug-in-Nig.pdf. Accessed: 28 May 2024."},{"key":"key-10.7189\/jogh.14.03029-202406061748-R17","unstructured":"United Nations Industrial Development Organization. Pharmaceutical Sector Profile: Nigeria. Vienna: United Nations Industrial Development Organization; 2011. Available: https:\/\/www.unido.org\/sites\/default\/files\/2011-04\/Nigeria_Pharma%20Sector%20Profile_032011_Ebook_0.pdf. Accessed: 29 March 2024."},{"key":"key-10.7189\/jogh.14.03029-202406061748-R18","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/S1473-3099(06)70581-3","article-title":"Counterfeit anti-infective drugs.","volume":"6","author":"Newton","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R19","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/bmj.317.7159.647","article-title":"Antimicrobial resistance in developing countries.","volume":"317","author":"Hart","year":"1998","journal-title":"BMJ"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R20","doi-asserted-by":"publisher","first-page":"6153","DOI":"10.1038\/s41467-023-41542-w","article-title":"The uncertain role of substandard and falsified medicines in the emergence and spread of antimicrobial resistance.","volume":"14","author":"Cavany","year":"2023","journal-title":"Nat Commun"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4269\/ajtmh.21-1133","article-title":"Modeling the Health and Economic Impact of Substandard and Falsified Medicines: A Review of Existing Models and Approaches.","volume":"107","author":"Ozawa","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R22","doi-asserted-by":"publisher","first-page":"e002393","DOI":"10.1136\/bmjgh-2020-002393","article-title":"A systematic review of substandard, falsified, unlicensed and unregistered medicine sampling studies: a focus on context, prevalence, and quality.","volume":"5","author":"McManus","year":"2020","journal-title":"BMJ Glob Health"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R23","unstructured":"World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (\u200eGLASS)\u200e Report: 2022. Geneva: World Health Organization; 2022. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240062702. Accessed: 22 April 2024."},{"key":"key-10.7189\/jogh.14.03029-202406061748-R24","doi-asserted-by":"publisher","first-page":"E11988","DOI":"10.1073\/pnas.1810840115","article-title":"Estimating the proportion of bystander selection for antibiotic resistance among potentially pathogenic bacterial flora.","volume":"115","author":"Tedijanto","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R25","doi-asserted-by":"publisher","first-page":"e68764","DOI":"10.7554\/eLife.68764","article-title":"Microbiome-pathogen interactions drive epidemiological dynamics of antibiotic resistance: A modeling study applied to nosocomial pathogen control.","volume":"10","author":"Smith","year":"2021","journal-title":"eLife"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R26","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.tim.2019.06.004","article-title":"Bystander Selection for Antimicrobial Resistance: Implications for Patient Health.","volume":"27","author":"Morley","year":"2019","journal-title":"Trends Microbiol"},{"key":"key-10.7189\/jogh.14.03029-202406061748-R27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1186\/s12913-017-2610-8","article-title":"Cost benefit of investment on quality in pharmaceutical manufacturing: WHO GMP pre- and post-certification of a Nigerian pharmaceutical manufacturer.","volume":"17","author":"Anyakora","year":"2017","journal-title":"BMC Health Serv Res"}],"container-title":["Journal of Global Health"],"original-title":[],"link":[{"URL":"https:\/\/jogh.org\/2024\/jogh-14-03029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T16:29:41Z","timestamp":1717691381000},"score":1,"resource":{"primary":{"URL":"https:\/\/jogh.org\/2024\/jogh-14-03029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7189\/jogh.14.03029","relation":{},"ISSN":["2047-2978","2047-2986"],"issn-type":[{"value":"2047-2978","type":"print"},{"value":"2047-2986","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"article-number":"03029"}}